Risk Stratification Using $^{18}$F-FDG PET/CT and Artificial Neural Networks in Head and Neck Cancer Patients Undergoing Radiotherapy

Sebastian N. Marschner $^{1,*,†}$, Elia Lombardo $^{1,2,4}$, Lena Minibek $^1$, Adrien Holzgreve $^3$, Lena Kaiser $^3$, Nathalie L. Albert $^3$, Christopher Kurz $^{1,2}$, Marco Riboldi $^2$, Richard Späth $^1$, Philipp Baumeister $^4$, Maximilian Niyazi $^1$, Claus Belka $^{1,5}$, Stefanie Corradini $^{1,6}$, Guillaume Landry $^{1,2}$ and Franziska Walter $^1$

1. Introduction

Advances in radiation oncology and medical imaging are closely linked, as attested by the widespread use of image guided radiotherapy (IGRT) and, more recently, the successful implementation of MR guided radiotherapy [1,2]. The past decade has seen strong growth in the extraction of quantitative features from medical imaging which can be used in predictive models; a practice called radiomics [3]. The application of machine learning provides the possibility of processing a high number of heterogeneous parameters obtained...
from clinical imaging data. Using artificial intelligence algorithms and specifically neural networks for machine learning allows for processing large amounts of data for predictive model building [4]. This development has the potential to translate into clinical practice by guiding treatment decisions and therapy planning, especially in an imaging driven field such as radiation oncology [5], where for instance several studies [6–8] showcased how deep learning could be used for head and neck cancer outcome prediction based on pretreatment CTs. Imaging with PET/CT using 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose (2-[\(^{18}\)F]FDG) is routinely part of pretreatment workup in several tumor entities such as squamous cell carcinoma of the head and neck (HNSCC) and allows extraction of several features. It has been shown that the diagnostic value of 2-[\(^{18}\)F]FDG PET/CT has an impact on therapy decisions in HNSCC [9–12]. The prognostic value of several first order PET features, such as maximum of the standardized uptake value (SUV\(_{\text{max}}\)) or total lesion glycolysis (TLG) [13–15], has been previously studied. In PET images, volumes of interests (VOIs) can be defined semi-automatically based on the tracer-uptake, eliminating the need to manually define VOIs for radiomics evaluation, allowing for high-throughput user-independent evaluation.

Today the cornerstone of treatment decision making in radiation therapy of HNSCC is the knowledge of risk factors that are well described in the literature. These risk factors include clinical data (e.g., age, sex, smoking history), tumor classifications (e.g., TNM-Stage), and histological features (e.g., grading, HPV-status) [16–18]. HPV expression has been shown to be an independent prognostic factor for overall survival in patients with oropharyngeal carcinoma [17]. However, even among HPV negative tumors a wide range of different therapy responses are reported [19]. Therefore, means of further treatment stratification and personalized tailoring of therapy strategies are needed. Artificial neural networks (ANNs) [20] based on image features are a promising approach.

In this study, we investigated whether a neural network-based algorithm applied on PET features along with clinical data can provide prognostic information for head and neck cancer patients undergoing curative radiotherapy in terms of locoregional failure (LRF) and overall survival (OS). This approach is novel since it relies entirely on features extracted from semi-automatically generated PET VOIs, and is thus not relying on expert segmentation. We specifically evaluated the impact of input feature selection on the neural network’s performance.

2. Materials and Methods

Approval by the Institutional Ethics Committee of LMU Munich (protocol code No. 448-13 (date of approval 21 October 2013) for the retrospective data evaluation was available in the context of the clinical cooperation group (KKG) “Personalized radiotherapy for head and neck tumors”.

2.1. Patients

We identified patients who underwent curative therapy according to international guidelines with either complete surgery with neck dissection and adjuvant (chemo)radiotherapy (RCT) or definitive RCT for primary head and neck tumors between 06/08 and 02/20. Only patients with pre-treatment 2-[\(^{18}\)F]FDG PET/CT, older than 18 years, and with a follow-up history of at least 1 year were included. Tumor stage was assessed using the UICC 7th edition classification [21]. Patient and tumor characteristics, as well as the treatment modalities, were evaluated. A complete list of the clinical features is given in Table A1 in the Appendix B.

Follow-up has been calculated from the first day of the definitive or adjuvant RCT. The events of the survival endpoints were defined as follows: overall survival (OS)—time in months from first day of radiotherapy until death, and locoregional failure (LRF)—defined as local or regional recurrence histologically proven by needle biopsy or surgery.
2.2. 2-\textsuperscript{18}F-FDG PET/CT Imaging Protocol

Whole-body PET/CT images were acquired on a Biograph mCT Flow 20-4R PET/CT scanner (Siemens, Healthcare GmbH, Erlangen, Germany) and a GE Discovery 690 PET/CT scanner (General Electric, Munich, Germany) as previously reported [22–24]. Patients fasted at least 4 h prior to administration of approximately 250 MBq 2-deoxy-2-\textsuperscript{18}F-fluoro-D-glucose (2-\textsuperscript{18}F)FDG, and emission scan acquisition of the immobilized head and neck, thorax, abdomen, and pelvis started approximately 60 min after intravenous tracer administration. Unless contraindicated, iodine-containing contrast medium (Ultravist 300, Bayer Vital GmbH, Leverkusen, Germany or Imeron 350, 2.5 mL/s, Bracco Imaging Deutschland GmbH, Konstanz, Germany) was administered for diagnostic computed tomography (CT) imaging (100–190 mAs, 120 kV; portal venous phase).

2.3. Feature Extraction

Delineation of the tumor region from which the features were extracted was performed semi-automatically using the HERMES Browser (P5, Gold, Version 4.17; HERMES Medical Solutions AB, Stockholm, Sweden) with the true attenuation corrected (AC) reconstruction. Firstly, a broad ROI was labeled by an expert physician. The SUV\textsubscript{max} and SUV\textsubscript{peak} representing the mean SUV of the voxels within a 1 cm\textsuperscript{3} cubic VOI around SUV\textsubscript{max} were determined by the software. Then multiple volumes of interest (VOIs) of the area of the primary tumor covered with 25% (SUV25), 40% (SUV40), 50% (SUV50), 75% (SUV75), and 90% (SUV90) of the SUV\textsubscript{max} or more were automatically delineated. SUV\textsubscript{min} and SUV\textsubscript{mean} were determined, and the mean tumor volume (MTV) and total lesion glycolysis (TLG) were calculated for every VOI. Additionally, SUV\textsubscript{mean} liver [25], SUV\textsubscript{mean} cervical spine [26], and SUV\textsubscript{mean} aorta were defined via delineation and a set of ratios were calculated [27] as follows.

\textbf{SUR\textsubscript{max}} – Ratio (SUR\textsubscript{max}):

\[ \text{SUR}_{\text{max}} \text{ Organ} = \frac{\text{SUV}_{\text{max}} \text{ Tumor}}{\text{SUV}_{\text{mean}} \text{ Organ}} \]  \hspace{1cm} (1)

\textbf{SUR\textsubscript{mean}} – Ratio (SUR\textsubscript{mean}):

\[ \text{SUR}_{\text{mean}} \text{ Organ} = \frac{\text{SUV}_{\text{mean}} \text{ of SUV}_{40, 50, 75 \text{ or } 90}}{\text{SUV}_{\text{mean}} \text{ Organ}} \]  \hspace{1cm} (2)

\textbf{SUR\textsubscript{TLG}} Organ:

\[ \text{SUR}_{\text{TLG}} \text{ Organ} = \frac{\text{TLG of SUV}_{40, 50, 75 \text{ or } 90}}{\text{SUV}_{\text{mean}} \text{ Organ}} \]  \hspace{1cm} (3)

2.4. Data Preprocessing

Our input covariates comprised both numerical (e.g., age, SUV values, etc.) and categorical (e.g., sex, tumor site, etc.) data. Missing observations for the numerical values (2.6% on average, range 0.4% to 7.0%, excluding all covariates where no observation was missing) were replaced with the median value for that covariate while missing observations for categorical values (2.8% on average, range 0.4% to 8.7%, excluding all covariates where no observation was missing, grading and HPV-status, see below) were replaced with the most common class for that covariate. Z-score normalization was applied to the numerical variables to have zero mean and unit variance. The standardization was fitted on the
training data and then applied without changes to both training and testing numerical covariates (see Model Optimization and Details subsection for the adopted training and testing data subdivision). The categorical variables were one-hot encoded, meaning that, e.g., for the sex variable, a male was represented as a 2D-vector with a one in the first entry and a zero in the second entry and a female was represented as a 2D-vector with a zero in the first entry and a one in the second entry of the vector. For the grading and HPV-status categorical variables, the number of missing observations was particularly high, amounting to 13.9% and 41.3% of all patients. Therefore, instead of replacing missing observations with the most common category, we considered ‘unknown status’ as an extra category for the one-hot encoding procedure.

2.5. Feature Selection

Within this study, three different feature selection methods were used. To build the first set of input variables, an advanced dimensionality reduction algorithm called Uniform Manifold Approximation and Projection (UMAP) [28] was leveraged to automatically extract as much information as possible from all the available covariates. The UMAP algorithm constructs an abstract high-dimensional representation of the input data and then optimizes a low-dimensional representation to be as structurally similar as possible to the high-dimensional one. In other words, the UMAP algorithm can convert a high number of initial (and potentially redundant) features into a small number of new features (embedding), trying to preserve all information contained in the initial set. We fitted the UMAP algorithm on the training data and then applied it to both training and testing data to generate the embeddings. To compare the predictive performance of a model using an automatically extracted embedding of features as input, we built two additional models based on two different sets of features selected from all the available covariates by an expert radiation oncologist.

The first physician-selected feature set comprises classical clinical covariates which have been shown to be predictive in previous studies and which would be available without 2-[\textsuperscript{18}F]FDG PET/CT [19]. We called this set of input variables Literature Only (LO) features and used it as baseline to evaluate whether additional PET features could improve the results. The selected variables are described in Table 1.

| Table 1. Selected features for LO and LP. |
|------------------------------------------|
| **Literature Only (LO)**                  |
| **Clinical values**                      |
| Age at diagnosis                         |
| Gender                                   |
| T-Stage                                  |
| N-Stage                                  |
| Tumor grading                            |
| HPV-status                               |
| Smoking status                           |
| **PET values**                           |
| none                                     |
| **Literature + PET (LP)**                |
| **Clinical values**                      |
| Age at diagnosis                         |
| Gender                                   |
| T-Stage                                  |
| N-Stage                                  |
| Tumor grading                            |
| HPV-status                               |
| Smoking status                           |
| **PET values**                           |
| SUV\textsubscript{40}max                 |
| SUV\textsubscript{40}peak                |
| SUV\textsubscript{40}TLG                 |
| SUR\textsubscript{max} Liver             |
| SUR\textsubscript{max} Spine             |
| SUR\textsubscript{max} Aorta             |
| SUV\textsubscript{mean} Liver            |
| SUV\textsubscript{mean} Spine            |
| SUV\textsubscript{mean} Aorta            |

The second physician-selected feature set comprises the same LO features plus some expert-selected PET features that are easily extractable from every diagnostic PET software and with a focus on SUR\textsubscript{max}, SUR\textsubscript{mean}, and SUR\textsubscript{TLG}. We called this set of variables Literature and PET (LP) features. The selected PET features are listed in Table 1. While
final physician feature selection is presented in the results section, this was done only once prior to model optimization.

2.6. Artificial Neural Network

In this work, we used Nnet-survival [29], a non-linear adaptation of the Cox proportional hazards model, to extend a binary classification ANN to a survival analysis one. Our ANN can thus incorporate censoring information and outputs survival curves/recurrence-free probability curves as a function of time for every patient.

2.7. Model Optimization and Details

The overall workflow used in this study is shown in Figure A1. The training/validation data and the testing data were obtained by randomly taking 75% and 25% out of the entire dataset of 230 patients. This procedure was done only once, prior to all trainings. The 172 training and validation patients were used to find the best hyper-parameters of the models. Specifically, for each ANN applied to a different embedding, we performed an automatic grid search over all 18 combinations of the learning rate ($1 \times 10^{-4}, 5 \times 10^{-4}$ and $1 \times 10^{-3}$), the number of hidden layers (1, 2), and the number of neurons in the hidden layer (5, 10, 15). When the ANN was applied to the expert knowledge features, the grid search was performed only once over the 18 above-mentioned combinations. On the other hand, the algorithmic UMAP dimensionality reduction has its own parameters: specifically, we decided to vary the number of nearest neighbors (5, 15, 25, 50), which controls how UMAP balances local versus global structure of the data and the number of features of the embedding (5, 15, 25, 50). Thus, when performing the grid search for the UMAP + ANN model we looked at all 18 combinations for the ANN and at all 16 combinations for the UMAP at the same time, leading to a grid search over 288 different combinations. For each of the combinations a 3-fold cross-validation was used and the hyper-parameters, which led to the best validation performance when averaged over the three sub-folds were selected for the final ANN. As we had three different feature sets as input to the ANN, three different sets of hyper-parameters were found per endpoint. Table 2 shows a summary of the best hyper-parameters, which were consequently used for the testing phase.

Table 2. Sets of best hyper-parameters found for the different models by performing 3-fold cross validation with several different hyper-parameter combinations.

| Endpoint | Model       | Nearest Neighbors | Number of Features | Learning Rate | Number of Hidden Layers | Neurons per Hidden Layer |
|----------|-------------|-------------------|-------------------|---------------|-------------------------|-------------------------|
|          | UMAP + ANN  | 5                 | 50                | $1 \times 10^{-3}$ | 2                       | 10                      |
|          | LO + ANN    | -                 | -                 | $1 \times 10^{-4}$ | 2                       | 10                      |
|          | LP + ANN    | -                 | -                 | $1 \times 10^{-3}$ | 2                       | 5                       |
| LRF      | UMAP + ANN  | 50                | 15                | $1 \times 10^{-4}$ | 1                       | 10                      |
|          | LO + ANN    | -                 | -                 | $5 \times 10^{-4}$ | 2                       | 10                      |
|          | LP + ANN    | -                 | -                 | $1 \times 10^{-4}$ | 2                       | 15                      |

After the best set of hyper-parameters was found for each model, we repeated the 3-fold cross-validation once with the best set of hyper-parameters, leading to three different trained architectures per model (one for each cross-validation fold). To obtain a single testing set prediction out of the three networks, we performed model averaging, i.e., we applied all three models to the testing set and then averaged over their predictions before computing the evaluation metrics.
All code, from data pre-processing to model building, was written in Python 3.8. The networks were optimized using the high-level API Keras 2.4.3 with Tensorflow 2.3.0 as back-end. Training and testing were carried out on an NVIDIA Titan V with 12 GB of memory. We used a fixed weight decay [30] of $1 \times 10^{-4}$ and a dropout rate [31] of 25% to avoid overfitting. The exponential linear unit [32] was used as activation function and the Adam algorithm [33] to optimize the network weights. We set the number of neurons in the output layer to six and chose a time-gap of half a year between the different output time-points. Therefore, our ANN outputs time-to-event curves for a duration of three years (see Figure 1, on the right). For all ANNs a batch size of 32 and 3000 epochs were used for training. Keras early stopping callbacks with a patience of 1000 epochs were used to terminate training if no improvement in performance was observed.

![Figure 1](image.png)

**Figure 1.** Kaplan-Meier curves of high-risk (blue) and low-risk (orange) patient groups separated according to a threshold optimized during cross-validation. Significance of difference was assessed using the log-rank test. (a) Kaplan-Meier plots for OS endpoint. (b) Kaplan-Meier plots for LRF endpoint.

### 2.8. Statistical Analysis

The performance of the models was evaluated in two ways. First, we measured discriminative performance by using Harrell’s concordance index (HCI) [34]. HCI is commonly used in survival analysis as it quantifies for how many pairs of patients the predicted risk and the ground truth time-to-event or last follow-up time are concordant. HCI is normalized and amounts to 1.0 if all possible pairs are concordant and to 0.5 if we would assign random risks to the patients. Our model outputs time-to-event curves, so to compute HCI we have chosen the survival probability and additionally recurrence-free probability after two years as risk value. To obtain confidence intervals for the testing set HCI we used bootstrap re-sampling [34], i.e., we repeatedly took samples with replacement from the original testing set with 58 patients to generate many testing set variants. Specifically, we applied our models to 1000 bootstrap sets, therefore obtaining for each model 1000 HCIs. From these, we computed the median HCI with 83% confidence intervals (see Discussion for details on the choice of using 83% intervals).

In addition to HCI, we quantified the model’s capability of stratification into high- and low-risk testing patient groups. For this purpose, we first found a threshold during cross-validation by averaging over the risk of all patients with event, then averaging over the risk of all patients without event and finally taking the mean of these two values to set a threshold for all three cross-validation models, thus obtaining a single model averaged...
threshold. We then used this threshold to split the testing set into high-risk and low-risk patients and applied the log-rank test to infer whether the difference in the two groups was significant. Results with $p$-values < 0.05 were considered significant. To visualize patient stratification, Kaplan-Meier curves were used.

3. Results

3.1. Patients

We included 230 patients, with a median age of 64 (range 28–93), 167 (72.6%) male, and 63 (27.4%) female. Regarding UICC stage, 5 (2.2%) were staged UICC I, 25 (10.9%) UICC II, 45 (19.6%) UICC III, and 155 (67.4) UICC IV. A comprehensive analysis of patient characteristics and the allocation between training and testing cohort can be seen in Table A1 (Appendix B). Median follow up was 31 months (range 1–175 months), 55 patients experienced a loco-regional recurrence, and 123 patients died, leading to a mean OS of 40.5 months (range 0.3–151.1 months) and a mean LRC of 26.2 months (range 3.1–118.6 months). Forty-one patients received surgery with adjuvant RT and 32 patients received surgery with adjuvant RCT with a median overall dose of 64 Gy (range 61.4–70.0 Gy) to the tumor bed. Definitive RCT was received by 157 patients with a median overall dose to the tumor of 69.9 Gy (range 63–70.4 Gy) applied via 3D conformal or intensity-modulated radiotherapy (IMRT). Patients with extracapsular extension of the involved lymph nodes (ECE+), close or incomplete resection status additionally received chemotherapy. Subsequent chemotherapy was administered to 189 patients: Cisplatin/5-Fluorouracil (CDDP/5-FU in accordance with the ARO 96-3 Study), 5-Fluorouracil/MMC (Mitomycin C (MMC) 10 mg/m$^2$ d1, d29; 5-FU 600 mg/m$^2$ d1–5), Cisplatin mono (40 mg/m$^2$ weekly) or Cetuximab mono (Cetuximab 250 mg/m$^2$ weekly with 400 mg/m$^2$ loading dose).

3.2. Feature Extraction

For each of the 230 patients, 102 covariates were extracted in total. Out of these, 24 were clinical variables and 78 were PET-based variables. The size of the data matrix prior to the preprocessing step therefore equals 172 × 102 for cross-validation and 58 × 102 for testing. All PET-based variables are listed in Table A2 (Appendix B).

3.3. Data Preprocessing

After preprocessing, the size of the data matrix was 172 × 206 for the cross-validation set and 58 × 206 for the testing set due to the one-hot encoding procedure which increased the dimension of categorical variables.

3.4. Feature Selection

The size of the cross-validation and testing input feature matrix after UMAP was 172 × 50 and 58 × 50 for the OS endpoint and 172 × 15 and 58 × 15 for the LRF endpoint. The final number of features (50 for OS and 15 for LRF) is a hyper-parameter of the UMAP algorithm, so it was automatically determined during optimization. For the LO set, seven clinical variables were chosen by the expert physician, that is ‘Gender’, ‘Age at diagnosis’, ‘Tumor localization’, ‘T Stage’, ‘N Stage’, ‘Tumor grading’, and ‘HPV-p16 status’. After preprocessing, this yields an input data matrix of 172 × 43 for cross-validation and 58 × 43 for testing. For the LP set, we used the LO features plus nine expert selected PET variables, which are shown in Table 1. Therefore, 16 covariates in total were used. After preprocessing, this yields an input data matrix of 172 × 52 for cross-validation and 58 × 52 for testing.

3.5. Model Optimization and Details

The hyper-parameters found via cross-validation for the UMAP algorithm and the ANN are shown in Table 2. A 3-fold cross-validation took on average 2 min.
3.6. HCI Comparisons

With an HCI of 0.71 (0.64–0.78), the best performing model for OS was the ANN applied to literature and PET (LP) features selected by an expert physician. However, it should be noted that LP + ANN was slightly, yet not significantly, better than the other two models, as the confidence intervals overlapped. For LRF, we found the literature only based ANN, with an HCI of 0.70 (0.56–0.80), to be slightly better than the LP + ANN model; the UMAP + ANN model was inferior. The differences were again not significant in terms of confidence intervals (Table 3).

| Endpoint | Model        | 3-Fold Cross-Validation HCI  | Median Testing HCI  |
|----------|--------------|-------------------------------|---------------------|
|          |              | (83% Confidence Interval)    |                     |
| OS       | UMAP + ANN   | 0.63; 0.59; 0.64              | 0.64 (0.56–0.72)    |
|          | LO + ANN     | 0.59; 0.65; 0.66              | 0.67 (0.58–0.75)    |
|          | LP + ANN     | 0.58; 0.66; 0.59              | 0.71 (0.64–0.78)    |
| LRF      | UMAP + ANN   | 0.55; 0.76; 0.62              | 0.62 (0.50–0.75)    |
|          | LO + ANN     | 0.55; 0.59; 0.64              | 0.70 (0.56–0.80)    |
|          | LP + ANN     | 0.56; 0.55; 0.64              | 0.65 (0.54–0.76)    |

3.7. Risk Group Stratification

For OS, all three models achieved a significant stratification (UMAP + ANN $p = 0.01$; LO + ANN $p = 0.01$) although the separation of the two groups was more evident for the LP + ANN model ($p < 0.001$). For LRF, the LP + ANN model was the only one able to significantly divide the testing patients into high-risk and low-risk groups ($p = 0.03$). The UMAP + ANN model ($p = 0.8$) and LO + ANN ($p = 0.4$) showed worse performance in stratifying patients (Figure 1).

4. Discussion

Our results show that risk stratification for patients undergoing curative treatment for HNSCC using an ANN is feasible. By testing three different feature selection approaches, we were able to show that adding 2-$^{18}$F]FDG PET/CT features enhances the performance of the stratification process, however the differences were not statistically significant. Generally, due to the ANN’s black-box nature it is not possible to determine which covariates were used to perform the prediction, so it could not be explicitly inferred whether the additional usage of PET features is needed for the algorithm. Theoretically, an ANN based solely on clinical data could have been enough to achieve high prognosis performance on both endpoints. However, when looking at risk group stratification for OS, the use of additional PET features (LP + ANN) led to better results than without the PET data (LO + ANN). In fact, for LRF the LP + ANN model was the only one able to significantly stratify the testing patients in high-risk and low-risk groups. For OS, all three models achieved a significant stratification. However, we noted that the separation of the two groups was more evident for the LP + ANN models, making it the best model in this analysis and thus confirming the added value of the initial 2-$^{18}$F]FDG PET/CT. A similar result was reported in another study by Bogowicz et al. [35], where the additional information derived from 2-$^{18}$F]FDG PET/CT led to superior results for local tumor control modeling than standard CT.

However, this seems to be in contrast with the result that the UMAP + ANN model, to which all PET covariates were available, showed the worst performance. As visible from the results, UMAP found some relevant information from all available covariates, but this information could not be translated by the ANN into the best performing model. Similar results were described by Ger et al. when they tested radiomics features for their additional value in initial PET and CT images of HNSCC patients. They reported a worsening of the
AUC by adding radiomics features to volume of the tumor alone, showing that radiomics features are not automatically associated with survival and in general that using more features as input to a predictive model does not necessarily lead to improved results [36].

A similar potential explanation could therefore be that most of the covariates we extracted have no or only poor association with the selected endpoints, making it difficult for the UMAP + ANN to find predictive patterns. On the other hand, the finding that the LP + ANN model containing some of the PET covariates performed better than the clinical data alone (LO), suggested that at least some of the PET covariates do have an impact on the endpoints. This suggests that state-of-the-art dimensionality reduction algorithms may not be sufficient if too much unselected data is given as input.

Several studies have underlined the importance of the feature selection step prior to classification [37,38]. The superior performance of the expert knowledge features based ANNs (LO + ANN and LP + ANN) compared to the automatically extracted feature-based ANN (UMAP + ANN) suggests that not only feature selection is crucial, but also that expert knowledge can play a key role in the process. Under a clinical point of view, this result is of relevance as only a small number of known covariates would have to be collected for every patient. Within this study, 83% confidence intervals have been used for HCI as it can be shown [39,40] that if two 83% confidence intervals do not overlap, then the two-corresponding means/medians differ significantly with a significance level of 0.05, which corresponds to the statistical confidence usually reported in literature.

It has been underlined [41] how standardization of the different steps of radiomics model development will play a key role for the field to move forward. Although the Image Biomarker Standardization Initiative [42] represents a fundamental step in the standardization of feature calculation, better interpretability of the extracted features and standardization of the segmentation of the VOI from which the features are calculated remain challenging. In fact, in most radiomics studies the VOI is manually delineated by an expert radiologist or radiation oncologist [43], which introduces reproducibility issues and requires additional time if the segmentation is not part of the treatment workflow.

An advantage of our approach compared to traditional radiomics is that no manual contouring of VOIs is needed. Another advantage is that by using solely semi-automatically collected features with a commercial diagnostic software, reproducibility issues are minimized. Furthermore, the fact that neither additional software for recognizing or extracting features nor time to delineate VOIs is needed, fosters use in clinical routine.

ANNs have been successfully used for binary outcome prediction of cancer in multiple studies [44–47]. However, several authors [29,48,49] have underlined the importance of incorporating censoring information in the model optimization. In fact, in a binary classification model this information is simply discarded, and each patient’s outcome is either labeled as ‘event’ or ‘no-event’. On the other hand, a survival model (or for other endpoints than OS, a so-called time-to-event model) is built not only using the information on whether an event occurred or not, but also the information on when it occurred or if follow-up was interrupted at a certain time point (i.e., right-censoring). A standard method used for survival analysis and to predict the risk of an event is the Cox proportional hazards model [48]. In this work, we used Nnet-survival [29] to extend a binary classification ANN to a time-to-event model, therefore incorporating censoring information in our model.

The main limitation of this study is that we only included patients from a single center. However, the patient cohort consists of 230 patients including UICC Stages I-IV and patients undergoing adjuvant or definitive RCT. We therefore believe the cohort is representative and well suited for training and testing an ANN. An external validation is planned in the future and might serve not only to test the model’s reliability on patients from different centers, but also to reduce the large confidence intervals which were observed when measuring the model’s performance using HCI on the bootstrapped test set (as the number of testing patients would be larger).
5. Conclusions

This study could demonstrate the potential of ANNs by stratifying HNSCC patients in high and low risk groups and PET-features by further enhancing the stratification performance. Since the best results were obtained by expert feature preselection, we conclude that an arbitrarily large number of different input variables does not automatically lead to the best result, even when using a state-of-the-art dimensionality reduction technique such as UMAP. Further work is needed to confirm these results with external validation and to implement models like this one in prospective trials.

Author Contributions: Conceptualization, S.N.M., E.L. and G.L.; methodology, S.N.M., E.L., M.R., C.K., N.L.A. and G.L.; software, S.N.M., L.M., E.L., A.H. and L.K.; validation, E.L., C.K, M.R. and G.L.; formal analysis, E.L., M.R., G.L. and C.K.; investigation, S.N.M., E.L., A.H., L.M., G.L. and F.W.; resources, M.N., S.C., P.B., N.L.A. and C.B.; data curation, E.L., C.K., M.R. and G.L.; writing—original draft preparation, S.N.M. and E.L.; writing—review and editing, F.W., P.B., R.S. and G.L.; visualization, E.L. and S.N.M.; supervision, G.L., F.W., P.B., N.L.A., M.N., C.B. and S.C.; project administration, G.L. and F.W.; funding acquisition, G.L. and C.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partially funded by the Förderprogramm für Forschung und Lehre, (registration number 1084) of the LMU Munich Medical Faculty.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of LMU Munich (protocol codes No. 448-13 (date of approval 21 October 2013); No. 459-13 (date of approval: 19 December 2013); No. 17-116 (date of approval 10 July 2018) in the context of the clinical cooperation group (KKG) “Personalized radiotherapy for head and neck tumors”).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The clinical data presented in this study are available in Appendix B (Table A1).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

![Workflow of the proposed models](image_url)

**Figure A1.** Workflow of the proposed models. The input covariates are first split randomly into training and testing data and preprocessed. Then, three different feature selection methods are used, one algorithmic (UMAP) and two based on expert knowledge (LO and LP). An ANN extended with a previously published survival model is applied on the three different embeddings to predict time-to-event curves for each patient, as shown exemplarily for one patient.
### Table A1. Clinical features.

|                        | Training Cohort | Testing Cohort | Proportion of Training and Testing Cohort |
|------------------------|-----------------|----------------|-------------------------------------------|
|                        | Patients        | Percentage [%] | Patients | Percentage [%] | Training Cohort [%] | Testing Cohort [%] |
| **Age at Diagnosis** * |                 |                |          |                |                    |                    |
| <45                    | 9               | 5.20           | 4        | 7.00           | 69.2               | 30.8               |
| 45–65                  | 90              | 52.00          | 28       | 49.10          | 76.3               | 23.7               |
| >65                    | 74              | 42.80          | 25       | 43.90          | 74.7               | 25.3               |
| **Gender** *           |                 |                |          |                |                    |                    |
| male                   | 127             | 73.4           | 40       | 70.2           | 76.0               | 24.0               |
| female                 | 46              | 26.6           | 17       | 29.8           | 73.0               | 27.0               |
| **Tumor localization** |                 |                |          |                |                    |                    |
| Nasopharynx            | 11              | 6.4            | 4        | 7.0            | 73.3               | 26.7               |
| Oropharynx             | 58              | 33.5           | 22       | 38.6           | 72.5               | 27.5               |
| Oral Cavity            | 52              | 30.1           | 21       | 36.8           | 71.2               | 28.8               |
| Hypopharynx            | 27              | 15.6           | 4        | 7.0            | 87.1               | 12.9               |
| Larynx                 | 25              | 14.5           | 6        | 10.5           | 80.6               | 19.4               |
| **UICC Stage**         |                 |                |          |                |                    |                    |
| I                      | 5               | 2.9            | 0        | 0.0            | 100.0              | 0.0                |
| II                     | 17              | 9.8            | 8        | 14.0           | 68.0               | 32.0               |
| III                    | 35              | 20.2           | 10       | 17.5           | 77.8               | 22.2               |
| IV                     | 116             | 67.1           | 39       | 68.4           | 74.8               | 25.2               |
| **T Stage** *          |                 |                |          |                |                    |                    |
| T1                     | 17              | 9.8            | 5        | 8.8            | 77.3               | 22.7               |
| T2                     | 41              | 23.7           | 16       | 28.1           | 71.9               | 28.1               |
| T3                     | 57              | 32.9           | 9        | 15.8           | 86.4               | 13.6               |
| T4                     | 58              | 33.5           | 27       | 47.4           | 68.2               | 31.8               |
| **N Stage** *          |                 |                |          |                |                    |                    |
| N0                     | 40              | 23.1           | 10       | 17.5           | 80.0               | 20.0               |
| N1                     | 24              | 13.9           | 12       | 21.1           | 66.7               | 33.3               |
| N2                     | 97              | 56.1           | 30       | 52.6           | 76.4               | 23.6               |
| N3                     | 12              | 6.9            | 5        | 8.8            | 70.6               | 29.4               |
| **M Stage**            |                 |                |          |                |                    |                    |
| M0                     | 161             | 93.1           | 51       | 89.5           | 75.9               | 24.1               |
| M1                     | 8               | 4.6            | 4        | 7.0            | 66.7               | 33.3               |
| Mx                     | 4               | 2.3            | 2        | 3.5            | 66.7               | 33.3               |
| **Resection status**   |                 |                |          |                |                    |                    |
| R0                     | 17              | 9.8            | 8        | 14.0           | 68.0               | 32.0               |
| R0 (CM)                | 15              | 8.7            | 6        | 10.5           | 71.4               | 28.6               |
| R1                     | 14              | 8.1            | 3        | 5.3            | 82.4               | 17.6               |
| R2                     | 5               | 2.9            | 2        | 3.5            | 71.4               | 28.6               |
| No surgery/unknown     | 122             | 70.5           | 38       | 66.7           | 76.3               | 23.8               |
### Table A1. Cont.

| Training Cohort | Testing Cohort | Proportion of Training and Testing Cohort |
|-----------------|----------------|------------------------------------------|
|                 | Patients       | Percentage [%] | Patients       | Percentage [%] | Training Cohort [%] | Testing Cohort [%] |
| **Lymphovascular invasion** |                |               |                |               |               |               |
| L0              | 29             | 16.8          | 15             | 26.3          | 65.9          | 34.1          |
| L1              | 18             | 10.4          | 1              | 1.8           | 94.7          | 5.3           |
| No surgery/unknown | 126           | 72.8          | 41             | 71.9          | 75.4          | 24.6          |
| **Venous tumor invasion** |                |               |                |               |               |               |
| V0              | 38             | 22.0          | 16             | 28.1          | 70.4          | 29.6          |
| V1              | 7              | 4.0           | 1              | 1.8           | 87.5          | 12.5          |
| No surgery/unknown | 128           | 74.0          | 40             | 70.2          | 76.2          | 23.8          |
| **Perineural invasion** |                |               |                |               |               |               |
| Pn0             | 26             | 15.0          | 11             | 19.3          | 70.3          | 29.7          |
| Pn1             | 9              | 5.2           | 3              | 5.3           | 75.0          | 25.0          |
| No surgery/unknown | 138           | 79.8          | 43             | 75.4          | 76.2          | 23.8          |
| **Tumor grading** |                |               |                |               |               |               |
| G1              | 8              | 4.6           | 0              | 0.0           | 100.0         | 0.0           |
| G2              | 77             | 44.5          | 25             | 43.9          | 75.5          | 24.5          |
| G3              | 67             | 38.7          | 21             | 36.8          | 76.1          | 23.9          |
| No surgery/unknown | 21            | 12.1          | 11             | 19.3          | 65.6          | 34.4          |
| **Extracapsular enhancement** |            |               |                |               |               |               |
| ECE neg         | 44             | 25.4          | 19             | 33.3          | 69.8          | 30.2          |
| ECE pos.        | 16             | 9.2           | 3              | 5.3           | 84.2          | 15.8          |
| No surgery/unknown | 113           | 65.3          | 35             | 61.4          | 76.4          | 23.6          |
| **HPV-P16 status** |                |               |                |               |               |               |
| HPV neg         | 73             | 42.2          | 17             | 29.8          | 81.1          | 18.9          |
| HPV pos         | 26             | 15.0          | 19             | 33.3          | 57.8          | 42.2          |
| unknown/ not applicable | 74         | 42.8          | 21             | 36.8          | 77.9          | 22.1          |
| **Smoking status** |                |               |                |               |               |               |
| Nonsmoker       | 0              | 0.0           | 0              | 0.0           | 0.0           | 0.0           |
| Smoker          | 158            | 91.3          | 52             | 91.2          | 75.2          | 24.8          |
| unknown         | 15             | 8.7           | 5              | 8.8           | 75.0          | 25.0          |
| **Therapy regime** |                |               |                |               |               |               |
| OP + RT         | 27             | 15.6          | 14             | 24.6          | 65.9          | 34.1          |
| OP + RCT        | 25             | 14.5          | 7              | 12.3          | 78.1          | 21.9          |
| RCT             | 121            | 69.9          | 36             | 63.2          | 77.1          | 22.9          |
| **Death**       |                |               |                |               |               |               |
| No              | 79             | 45.7          | 28             | 49.1          | 73.8          | 26.2          |
| Yes             | 94             | 54.3          | 29             | 50.9          | 76.4          | 23.6          |

Patient characteristics * Values used for LO and LP set.
Table A2. Collected PET values.

| SUV Values Tumor | SUV Ratio (SUR) | SUV Values Organ |
|------------------|----------------|-----------------|
| mean             | SURmax Liver *| SUVmean *       |
| min              | SURmean Liver  | SUVmin          |
| max *            | SURTLG Liver   | SUVmax          |
| median           | SURmax Spine * | SUVmedian       |
| peak *           | SURmean Spine  | MTV             |
| MTV              | SURTLG Spine   | TLG             |
| TLG *            | SURmax Aorta * | SUVmean *       |
| mean             | SURmean Aorta  | Aorta           |
| min              | SURmax Liver   | SUVmin          |
| max              | SURmean Liver  | MTV             |
| median           | SURTLG Aorta   | TLG             |
| peak             | SURTLG Aorta   | SUVmean *       |
| MTV              | SURmax Spine   | SUVmax          |
| TLG              | SURmean Spine  | SUVmedian       |
| mean             | SURTLG Spine   | Liver           |
| min              | SURmax Aorta   | SUVmin          |
| max              | SURmean Aorta  | MTV             |
| median           | SURTLG Aorta   | TLG             |
| peak             | SURmax Liver   | Aorta           |
| MTV              | SURmean Liver  | SUVmin          |
| TLG              | SURTLG Liver   | SUVmax          |
| mean             | SURmax Spine   | SUVmedian       |
| min              | SURmean Spine  | MTV             |
| max              | SURTLG Spine   | TLG             |
| median           | SURmax Aorta   | SUVmean *       |
| peak             | SURmean Aorta  | SUVmax          |
| MTV              | SURTLG Aorta   | SUVmedian       |
| TLG              | SURmax Liver   | Liver           |

* Values used for LO and LP set.
References

1. Rogowski, P.; von Bestenbostel, R.; Walter, E.; Straub, K.; Nierer, L.; Kurz, C.; Landry, G.; Reiner, M.; Auernhammer, C.J.; Belka, C.; et al. Feasibility and early clinical experience of online adaptive mr-guided radiotherapy of liver tumors. *Cancers* 2021, 13, 1523. [CrossRef] [PubMed]

2. Corradini, S.; Alongi, F.; Andratschke, N.; Belka, C.; Boldrini, L.; Cellini, F.; Debus, J.; Guckenberger, M.; Hörner-Rieber, J.; Lagerwaard, F.J.; et al. MR-guidance in clinical reality: Current treatment challenges and future perspectives. *Radiat. Oncol.* 2019, 14, 92. [CrossRef]

3. Kumar, V.; Gu, Y.; Basu, S.; Berglund, A.; Eschrich, S.A.; Schabath, M.B.; Forster, K.; Aerts, H.J.W.L.; Dekker, A.; Fenstermacher, D.; et al. Radiomics: The process and the challenges. *Magn. Reson. Imaging* 2012, 30, 1234–1248. [CrossRef] [PubMed]

4. Giraud, P.; Giraud, P.; Gasnier, A.; El Ayachy, R.; Kreps, S.; Foy, J.P.; Durdux, C.; Huguet, F.; Burgun, A.; Bibault, J.-E. Radiomics and machine learning for radiotherapy in head and neck cancers. *Front. Oncol.* 2019, 9, 174. [CrossRef] [PubMed]

5. Peeken, J.C.; Nüsslin, F.; Combs, S.E. “Radio-oncomics”: The potential of radiomics in radiation oncology. *Strahlenther. Onkol.* 2017, 193, 767–779. [CrossRef] [PubMed]

6. Diamant, A.; Chatterjee, A.; Vallières, M.; Shenouda, G.; Seuntjens, J. Deep learning in head & neck cancer outcome prediction. *Sci. Rep.* 2019, 9, 2764. [CrossRef]

7. Starke, S.; Leger, S.; Zwanenburg, A.; Leger, K.; Lohaus, F.; Linge, A.; Schreiber, A.; Kalinauskaite, G.; Tinhofer, I.; Guberina, N.; et al. 2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. *Sci. Rep.* 2020, 10, 15625. [CrossRef]

8. Lombardo, E.; Kurz, C.; Marschner, S.; Avanzo, M.; Gagliardi, V.; Fanetti, G.; Franchin, G.; Stancanello, J.; Corradini, S.; Niyazi, M.; et al. Distant metastasis time to event analysis with CNNs in independent head and neck cancer cohorts. *Sci. Rep.* 2021, 11, 6418. [CrossRef]

9. Unterrainer, M.; Eze, C.; Ilhan, H.; Marschner, S.; Roengvoraphoj, O.; Schmidt-Hegemann, N.S.; Walter, F.; Kurz, W.G.; af Rosenschöld, P.M.; Jeraj, R.; et al. Recent advances of PET imaging in clinical radiation oncology. *Radiat. Oncol.* 2020, 15, 88. [CrossRef]

10. Birken Christensen, C.; Loft-Jakobsen, A.; Munc af Rosenschöld, P.; Hoigjard, L.; Roed, H.; Berthelsen, A.K. 18F-FDG PET/CT for planning external beam radiotherapy alters therapy in 11% of 581 patients. *Clin. Physiol. Funct. Imaging* 2018, 38, 278–284. [CrossRef]

11. Goel, R.; Moore, W.; Sumer, B.; Khan, S.; Sher, D.; Subramaniam, R.M. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. *Am. J. Roentgenol.* 2017, 209, 289–303. [CrossRef]

12. Pedraza, S.; Ruiz-Alonso, A.; Hernández-Martínez, A.C.; Cabello, E.; Lora, D.; Pérez-Regadera, J.F. 18F-FDG PET/CT in staging and delineation of radiotherapy volume for head and neck cancer. *Rev. Esp. Med. Nucl. Imagen Mol.* 2019, 38, 154–159. [CrossRef] [PubMed]

13. Cacicedo, J.; Fernandez, I.; del Hoyo, O.; Navarro, A.; Gomez-Iturriaga, A.; Pijoan, J.I.; Martinez-Indart, L.; Escudero, J.; Gomez-Suarez, J.; Zarate, R.O.; et al. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma. *Clin. Transl. Oncol.* 2017, 19, 1337–1349. [CrossRef]

14. Martens, R.M.; Noji, D.P.; Koopman, T.; Zweerijnen, B.; Heymans, M.; de Jong, M.C.; Hooekstra, O.S.; Vergeer, M.R.; de Bree, R.; Leemans, C.R.; et al. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. *Eur. J. Radiol.* 2019, 113, 59–90. [CrossRef]

15. Cheng, N.M.; Hsieh, C.E.; Liao, C.T.; Ng, S.H.; Wang, H.M.; Fang, Y.H.D.; Chou, W.C.; Lin, C.Y.; Yen, T.C. Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma with High-Risk Histology. *Clin. Nucl. Med.* 2019, 44, 351–358. [CrossRef]

16. Maihofer, C.; Schüttrumpf, L.; Macht, C.; Pfugradt, U.; Hess, J.; Schneider, L.; Woischke, C.; Walch, A.; Baumeister, P.; Kirchner, T.; et al. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck—clinical results from the cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer“. *Radiat. Oncol.* 2018, 13, 123. [CrossRef] [PubMed]

17. Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N. Engl. J. Med.* 2010, 363, 24–35. [CrossRef] [PubMed]

18. O’Sullivan, B.; Huang, S.H.; Siu, L.L.; Waldron, J.; Zhao, H.; Perez-Ordonez, B.; Weinreb, I.; Kim, J.; Ringash, J.; Bayley, A.; et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. *J. Clin. Oncol.* 2013, 31, 543–550. [CrossRef] [PubMed]

19. Hess, J.; Unger, K.; Maihofer, C.; Schüttrumpf, L.; Wintergerst, L.; Heider, T.; Weber, P.; Marschner, S.; Braselmann, H.; Samaga, D.; et al. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. *Clin. Cancer Res.* 2019, 25, 1505–1516. [CrossRef]

20. Shen, C.; Nguyen, D.; Zhou, Z.; Jiang, S.B.; Dong, B.; Jia, X. An introduction to deep learning in medical physics: Advantages, potential, and challenges. *Phys. Med. Biol.* 2020, 65, 05TR01. [CrossRef]

21. Sobin, L.H.; Gospodarowicz, M.K.; Wittekind, C. *TNM Classification of Malignant Tumours*, 7th ed.; International Union Against Cancer: Geneva, Switzerland, 2011.
46. Deist, T.M.; Dankers, F.J.W.M.; Valdes, G.; Wijsman, R.; Hsu, I.C.; Oberije, C.; Lustberg, T.; van Soest, J.; Hoebers, F.; Jochems, A.; et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. *Med. Phys.* 2018, **45**, 3449–3459. [CrossRef] [PubMed]

47. Wang, H.; Zhou, Z.; Li, Y.; Chen, Z.; Lu, P.; Wang, W.; Liu, W.; Yu, L. Comparison of machine learning methods for classifying mediastinal lymph node metastasis of non-small cell lung cancer from 18F-FDG PET/CT images. *EJNMMI Res.* 2017, **7**, 11. [CrossRef] [PubMed]

48. Ching, T.; Zhu, X.; Garmire, L.X. Cox-nnet: An artificial neural network method for prognosis prediction on high-throughput omics data. *BioRxiv* 2016, 093021. [CrossRef]

49. Katzman, J.L.; Shaham, U.; Cloninger, A.; Bates, J.; Jiang, T.; Kluger, Y. DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. *BMC Med. Res. Methodol.* 2018, **18**, 24. [CrossRef]